News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Canada (BMY) Commercializes ERBITUX(TM) for Advanced Colorectal Cancer


10/29/2008 4:25:34 PM

MONTREAL, Oct. 29 /CNW Telbec/ - In keeping with its commitment to extend and enhance the lives of Canadians through ongoing innovation, Bristol-Myers Squibb Canada (BMS) announced today the commercialization of its innovative cancer medication ERBITUX(TM) (cetuximab). This news is extremely important to Canadian physicians and their patients suffering from colorectal cancer who have exhausted other available treatments because it will give them a new option to fight this deadly disease.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES